nach oben

Tumor Biology

Erschienen in:

01.12.2014 | Research Article

Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma

verfasst von: Chong-Ling Duan, Gui-Hua Hou, Yan-Ping Liu, Ting Liang, Jing Song, Jian-Kui Han, Chao Zhang

Erschienen in: Tumor Biology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Endoglin is a proliferation-associated cell membrane antigen and overexpressed in the angiogenic vasculature of solid tumors. However, the applications of endoglin (ENG)-targeted radioimmunotheray in hepatocellular carcinoma have not been reported yet. Therefore, the aim of this study was the visualization of both the development of hepatocellular carcinoma (HCC) tumor burden and therapeutic effect with ENG-targeted ¹³¹I-anti-ENG mAb (A8), via in vivo noninvasive fluorescence imaging (NIFLI) of SMMC7721-green fluorescent protein (GFP) cells. A8 showed a dose-dependent, time-dependent suppression on the proliferation of SMMC7721-GFP cells and human umbilical vein endothelial cells (HUVECs) in vitro. Tube formation assay showed that ¹³¹I-A8 markedly inhibits HUVECs to form extensive and enclosed tube networks. The results showed that the radiochemical purity of ¹³¹I-A8 was 92.8 % and ¹³¹I-A8 maintained more stable in serum than in saline and had high affinity against SMMC7721-GFP cells. The pharmacokinetics of ¹³¹I-A8 was in accordance with the two-compartment model, with a rapid distribution phase and a slow decline phase. NIFLI exhibited a good relation between the fluorescent signal and tumor volume in vivo. Furthermore, treatment with ¹³¹I-A8 resulted in significant tumor-growth suppression on the basis of the reducing fluorescent signal and a remarkably decreased tumor weight in treated animals. These results were further verified by RT-PCR and immunohistochemistry staining. Our findings indicate that ¹³¹I-A8 can be used as ENG-targeted therapy for hepatocellular carcinoma, and noninvasive fluorescence imaging provides valuable information on tumor burden and effectiveness of therapy.

Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008;12:2189–204.PubMedPubMedCentral

Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology. 2009;137:26–9.PubMed

Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;31:461–76.PubMed

Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer. 2009;125:388–97.PubMed

Marrero JA, Welling T. Modern diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2009;13:233–47.PubMed

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.PubMed

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.PubMed

Beecken WD, Kramer W, Jonas D. New molecular mediators in tumor angiogenesis. J Cell Mol Med. 2000;4:262–9.PubMed

Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, et al. Endoglin: an accessory component of the TGF-β-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol. 2001;188:1–7.PubMed

10.

Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, et al. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer. 1999;81:568–72.PubMed

11.

Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–84.PubMed

12.

Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24:5764–74.PubMed

13.

Yang LY, Lu WQ, Huang GW, Wang W. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer. 2006;6:110.PubMedPubMedCentral

14.

Chen HJ, Yang BL, Chen YG, Lin Q, Zhang SP, Gu YF. A GFP-labeled human colon cancer metastasis model featuring surgical orthotopic implantation. Asian Pac J Cancer Prev. 2012;13:4263–6.PubMed

15.

Zhang Q, Du Y, Xue Z, Chi C, Jia X, Tian J. Comprehensive evaluation of the anti-angiogenic and anti-neoplastic effects of endostar on liver cancer through optical molecular imaging. Plose One. 2014;9:e 85559. doi:10.1371/journal.pone.0085559.

16.

Zhang C, Hou G, Liang T, Song J, Qu L, et al. A prospective study of macrophage migration inhibitory factor as a marker of inflammatory detection. J Cell Mol Med. 2009;13:4077–83.PubMed

17.

Hao PP, Liu YP, Yang CY, Liang T, Zhang C, Song J, et al. Evaluation of ¹³¹I-anti-angiotensin II type 1 receptor monoclonal antibody as a reporter for hepatocellular carcinoma. Plose One. 2014;9:e85002. doi:10.1371/journal.pone.0085002.

18.

Bonde MM, Hansen JT, Sanni SJ, Haunsø S, Gammeltoft S, Lyngsø C, et al. Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms. Plose One. 2010;5:e14135. doi:10.1371/journal.pone.0014135.

19.

Wu C, Wei J, Tian D, Feng Y, Miller RH, Wang Y. Molecular probes for imaging myelinated white matter in CNS. J Med Chem. 2008;51:6682–8.PubMedPubMedCentral

20.

Rhim JS, Tsai WP, Chen ZQ, Chen Z, Van Waes C, Burger AM, et al. A human vascular endothelial cell model to study angiogenesis and tumorigenesis. Carcinogenesis. 1998;19:673–81.PubMed

21.

Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res. 2000;60:4804–11.PubMed

22.

Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med. 2009;13:1371–80.PubMed

23.

He L, Zhou X, Qu C, Hu L, Tang Y, Zhang Q, et al. Musashi2 predicts poor prognosis and invasion inhepatocellular carcinoma bydriving epithelial-mesenchymal transitio. J Cell Mol Med. 2014;18:49–58.PubMed

24.

Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res. 1997;3:1031–44.PubMed

25.

Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41:864–80.PubMed

26.

Tam K. The roles of doxorubicin in hepatocellular carcinoma. ADMET DMPK. 2013;1:29–44.

27.

Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69:11–6.PubMed

28.

Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–74.PubMed

29.

Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012;72:1909–14.PubMedPubMedCentral

30.

Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.PubMedPubMedCentral

31.

Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, et al. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534–7.PubMed

32.

McAllister KA, Baldwin MA, Thukkani AK, Gallione CJ, Berg JN, Porteous ME, et al. Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. Hum Mol Genet. 1995;4:1983–5.PubMed

33.

Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast carcinoma vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999;59:856–61.PubMed

34.

Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate. 2002;51:268–75.PubMed

35.

Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, McAsey ME. Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol. 2000;96:224–8.PubMed

36.

Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M, et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery. 2002;131:S109–13.PubMed

37.

Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 2001;7:3410–5.PubMed

38.

Pruneri G, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, Raggi F, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol. 2002;118:817–20.PubMed

39.

Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene. 2002;21:8272–81.PubMed

40.

Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer. 2000;36:675–81.PubMed

41.

Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931–7.PubMed

42.

She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin(CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer. 2004;108:251–7.PubMed

43.

Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1017–24.PubMedPubMedCentral

44.

Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 2005;23:1295–311.PubMed

45.

Barnard A, Smith DK. Self-assembled multivalency: dynamic ligand arrays for high-affinity binding. Angew Chem Int Ed Engl. 2012;51:6572–81.PubMed

46.

Hu H, Liu J, Yao L, Yin J, Su N, Liu X, et al. Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model. Oncol Rep. 2012;27:1937–43.PubMed

47.

Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H, et al. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer. 2008;122:2266–73.PubMedPubMedCentral

48.

Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H, et al. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer. 2009;125:1446–53.PubMedPubMedCentral

Titel: Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma
verfasst von: Chong-Ling Duan
Gui-Hua Hou
Yan-Ping Liu
Ting Liang
Jing Song
Jian-Kui Han
Chao Zhang
Publikationsdatum: 01.12.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 12/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2529-1

Springer Medizin

Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma

Abstract

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer

Letter regarding Meade et al. entitled “Models of acute mucosal tolerance to radiotherapy alone applied to synchronous chemo-radiation schedules in head and neck cancer”

Significance of −1082A/G polymorphism of IL10 gene for progression of colorectal cancer and IL-10 expression

Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism

A triterpenoid saponin from Adenophora triphylla var. japonica suppresses the growth of human gastric cancer cells via regulation of apoptosis and autophagy

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie